Cargando…

Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy

Doxorubicin is one of the most widely used anti-cancer drugs, but side effects and selectivity problems create a demand for alternative drug delivery systems. Herein we describe a hybrid magnetic nanomaterial as a pH-dependent doxorubicin release carrier. This nanocarrier comprises magnetic iron oxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogueira, João, Soares, Sofia F., Amorim, Carlos O., Amaral, João S., Silva, Cláudia, Martel, Fátima, Trindade, Tito, Daniel-da-Silva, Ana L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024164/
https://www.ncbi.nlm.nih.gov/pubmed/31947577
http://dx.doi.org/10.3390/molecules25020333
_version_ 1783498371601793024
author Nogueira, João
Soares, Sofia F.
Amorim, Carlos O.
Amaral, João S.
Silva, Cláudia
Martel, Fátima
Trindade, Tito
Daniel-da-Silva, Ana L.
author_facet Nogueira, João
Soares, Sofia F.
Amorim, Carlos O.
Amaral, João S.
Silva, Cláudia
Martel, Fátima
Trindade, Tito
Daniel-da-Silva, Ana L.
author_sort Nogueira, João
collection PubMed
description Doxorubicin is one of the most widely used anti-cancer drugs, but side effects and selectivity problems create a demand for alternative drug delivery systems. Herein we describe a hybrid magnetic nanomaterial as a pH-dependent doxorubicin release carrier. This nanocarrier comprises magnetic iron oxide cores with a diameter of 10 nm, enveloped in a hybrid material made of siliceous shells and ĸ-carrageenan. The hybrid shells possess high drug loading capacity and a favorable drug release profile, while the iron oxide cores allows easy manipulation via an external magnetic field. The pH responsiveness was assessed in phosphate buffers at pH levels equivalent to those of blood (pH 7.4) and tumor microenvironment (pH 4.2 and 5). The nanoparticles have a loading capacity of up to 12.3 wt.% and a release profile of 80% in 5 h at acidic pH versus 25% at blood pH. In vitro drug delivery tests on human breast cancer and non-cancer cellular cultures have shown that, compared to the free drug, the loaded nanocarriers have comparable antiproliferative effect but a less intense cytotoxic effect, especially in the non-cancer cell line. The results show a clear potential for these new hybrid nanomaterials as alternative drug carriers for doxorubicin.
format Online
Article
Text
id pubmed-7024164
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70241642020-03-19 Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy Nogueira, João Soares, Sofia F. Amorim, Carlos O. Amaral, João S. Silva, Cláudia Martel, Fátima Trindade, Tito Daniel-da-Silva, Ana L. Molecules Article Doxorubicin is one of the most widely used anti-cancer drugs, but side effects and selectivity problems create a demand for alternative drug delivery systems. Herein we describe a hybrid magnetic nanomaterial as a pH-dependent doxorubicin release carrier. This nanocarrier comprises magnetic iron oxide cores with a diameter of 10 nm, enveloped in a hybrid material made of siliceous shells and ĸ-carrageenan. The hybrid shells possess high drug loading capacity and a favorable drug release profile, while the iron oxide cores allows easy manipulation via an external magnetic field. The pH responsiveness was assessed in phosphate buffers at pH levels equivalent to those of blood (pH 7.4) and tumor microenvironment (pH 4.2 and 5). The nanoparticles have a loading capacity of up to 12.3 wt.% and a release profile of 80% in 5 h at acidic pH versus 25% at blood pH. In vitro drug delivery tests on human breast cancer and non-cancer cellular cultures have shown that, compared to the free drug, the loaded nanocarriers have comparable antiproliferative effect but a less intense cytotoxic effect, especially in the non-cancer cell line. The results show a clear potential for these new hybrid nanomaterials as alternative drug carriers for doxorubicin. MDPI 2020-01-14 /pmc/articles/PMC7024164/ /pubmed/31947577 http://dx.doi.org/10.3390/molecules25020333 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nogueira, João
Soares, Sofia F.
Amorim, Carlos O.
Amaral, João S.
Silva, Cláudia
Martel, Fátima
Trindade, Tito
Daniel-da-Silva, Ana L.
Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy
title Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy
title_full Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy
title_fullStr Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy
title_full_unstemmed Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy
title_short Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy
title_sort magnetic driven nanocarriers for ph-responsive doxorubicin release in cancer therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024164/
https://www.ncbi.nlm.nih.gov/pubmed/31947577
http://dx.doi.org/10.3390/molecules25020333
work_keys_str_mv AT nogueirajoao magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy
AT soaressofiaf magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy
AT amorimcarloso magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy
AT amaraljoaos magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy
AT silvaclaudia magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy
AT martelfatima magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy
AT trindadetito magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy
AT danieldasilvaanal magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy